US5788979A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biodegradable coating with inhibitory properties for application to biocompatible materials
Assignee: Boston Scientific Scimed Inc
•
Filing: 1997-02-10
•
Granted: 1998-08-04
•
Expires: 2017-02-10
Abstract
Abstract A method is disclosed for coating a biomaterial to be placed in contact with a patient's blood flow to inhibit blood coagulation from adhering to the biomaterial that would otherwise result from such contact. A biodegradable material of liquid state compatible with the blood and tissue of the human body is prepared, and an anti-coagulant drug is incorporated into the liquid state of the biodegradable material to form a liquid coating material. The liquid coating material is adhesively applied to a surface of the biomaterial in a substantially continuous overlying layer having a formulation, pattern and thickness selected according to the period of time over which the coating material is to perform its anti-coagulant action. Thereafter the coating material is dried to a layer thickness less than about 100 microns for continuous disintegration thereof as a function of time when the layer is in contact with flowing blood. The method is utilized in an exemplary embodiment in which the biomaterial is a vascular stent.
Inventors
- 👤 Eckhard Alt
- 👤 Axel Stemberger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 05:29
CPC Classifications
A; A61; A61L; A61L31/00; A61L31/14; A61L31/16; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2/062; A61L31/08; A61L31/10; A61L31/148; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0047; A61L33/06; A61L33/064; A61L33/066; A61L33/068; A61L33/08; A61L33/12; A61L33/124; A61F2250/00; A61F2250/0058; A61F2250/0067; A61L2300/00; A61L2300/40; A61L2300/42; A61L2300/45; A61L2300/60; A61L2300/602; A61L2300/606; A61L2300/608; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/924
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
149 words
A method for coating a biomaterial to be placed in contact with a patient's blood to inhibit blood coagulation on the biomaterial that would otherwise result from such contact, comprising the steps of: preparing a biodegradable material in a liquid state which is compatible with the blood and tissue of the human body; incorporating at least an anti-coagulant drug into the liquid state of the biodegradable material to form a liquid coating material; and adhesively applying the liquid coating material to a surface of the biomaterial in a substantially continuous overlying layer having a formulation, pattern and thickness selected according to the period of time over which the coating material is to perform its anti-coagulant action, and thereafter drying the coating material to a layer thickness less than about 100 microns for continuous disintegration thereof as a function of time when said layer is in contact with flowing blood.
Claim 2
Independent Claim
149 words
A method for coating a biomaterial to be placed in contact with a patient's blood to inhibit blood coagulation on the biomaterial that would otherwise result from such contact, comprising the steps of: preparing a biodegradable material in a liquid state which is compatible with the blood and tissue of the human body; incorporating at least an anti-coagulant drug into the liquid state of the biodegradable material to form a liquid coating material; and adhesively applying the liquid coating material to a surface of the biomaterial in a substantially continuous overlying layer having a formulation, pattern and thickness selected according to the period of time over which the coating material is to perform its anti-coagulant action, and thereafter drying the coating material to a layer thickness less than about 100 microns for continuous disintegration thereof as a function of time when said layer is in contact with flowing blood.
Claim 3
Dependent Claim
21 words
The method of claim 1, wherein: said biodegradable material is prepared in a liquid state by inclusion of a solvent therewith.
Claim 4
Dependent Claim
44 words
The method of claim 1, wherein: said coating material further includes at least one additive of a preselected anti-thrombotic, anti-inflammatory, anti-proliferative, anti-stenotic, and antibiotic substance for timed release as the coating material disintegrates when the coated biomaterial is placed in contact with the blood.
Claim 5
Dependent Claim
74 words
The method of claim 3, wherein: said layer is a composite layer including a plurality of sub-layers, each having a formulation, pattern and thickness selected according to the period of time over which the coating material is to perform the action of the respective additive incorporated therein, including one sub-layer incorporating said anti-coagulant drug therein and another sub-layer incorporating said at least one of a preselected anti-thrombotic, anti-inflammatory, anti-proliferative, anti-stenotic, and antibiotic substance therein.
Claim 6
Dependent Claim
33 words
The method of claim 4, wherein: the plurality of sub-layers lie atop one another, with the outermost sub-layer overlying and furthest removed from said surface of the biomaterial incorporating said anti-coagulant drug therein.
Claim 7
Dependent Claim
27 words
The method of claim 5, wherein: the innermost sub-layer is directly overlying and in contact with said surface of the biomaterial and incorporates said anti-stenotic substance therein.
Claim 8
Dependent Claim
33 words
The method of claim 4, wherein: the formulation, pattern and thickness of each of said plurality of sub-layers are selected for a predetermined timed release of the respective additive incorporated in the sub-layer.
Claim 9
Dependent Claim
39 words
The method of claim 1, wherein: said biodegradable material is a biodegradable synthetic polymer selected from the group consisting of polyglycolic acids, polylactids, polyhydroxybutyrates, polyhydroxy-valeriates, polydioxanons, modified starches, gelatins, modified celluloses, polyglycols, polyacrylic acids, polymethacrylic acids, and blends thereof.
Claim 10
Dependent Claim
29 words
The method of claim 1, wherein: said biodegradable material is a natural or synthetic aliphatic or hydroxy polymer of lactic acid, glycolic acid, or mixed polymers or blends thereof.
Claim 11
Dependent Claim
15 words
The method of claim 1, wherein: said layer has a thickness of about 10 microns.
Claim 12
Dependent Claim
21 words
The method of claim 1, wherein: each sub-layer of said composite layer has a thickness of at least about 10 microns.
Claim 13
Dependent Claim
18 words
The method of claim 3, wherein: said layer has at least one region incorporating said anti-coagulant drug therein.
Claim 14
Dependent Claim
17 words
The method of claim 12, wherein: said layer has a second region incorporating said anti-stenotic substance therein.
Claim 15
Dependent Claim
65 words
The method of claim 1, wherein: said biomaterial is selected from the group consisting of a stent, a vascular prostheses, a heart valve prosthesis, a carbon fiber electrode, a pacemaker electrode, a defibrillation electrode, a polymer catheter, tubing used in blood transfusion apparatus, tubing used in a heart-lung machine, an oxygenator, a plastic mandrill, an intravenous canule, an arterial canule, and a suture material catheter.
Claim 16
Dependent Claim
43 words
The method of claim 13, wherein: said biomaterial is a vascular stent of tubular configuration, and said at least one region includes the inner surface of the tubular configuration, and said second region includes at least the outer surface of the tubular configuration.
Claim 17
Dependent Claim
23 words
The method of claim 1, wherein: said liquid coating material is adhesively applied to said biomaterial by painting it on said surface thereof.
Claim 18
Dependent Claim
23 words
The method of claim 1, wherein: said liquid coating material is adhesively applied to said biomaterial by spraying it on said surface thereof.
Claim 19
Dependent Claim
25 words
The method of claim 1, wherein: said liquid coating material is adhesively applied to said biomaterial by dipping said biomaterial into the liquid coating material.
Claim 20
Dependent Claim
43 words
The method of claim 1, including: incorporating a plurality of drugs into the liquid state of said biodegradable material to form the liquid coating material, said plurality of drugs being selected for synergism and each with a desired function and time release characteristic.
Claim 21
Dependent Claim
31 words
The method of claim 1, wherein: said biomaterial is a cardiac electrode adapted to be implanted in the body for use in at least one of stimulating and sensing the heart.
Claim 22
Dependent Claim
34 words
The method of claim 1, wherein: said anti-coagulant drug includes at least two drugs for simultaneously release during disintegration of the coating material layer to inhibit both plasmatic and thrombocytetriggered coagulation onto the biomaterial.
Claim 23
Dependent Claim
58 words
The method of claim 1, wherein: said biomaterial is a vascular stent of tubular configuration, and said layer is composed of material selected to render the layer sufficiently elastic to maintain its integrity despite change in the dimensions of the surface of the stent on which said layer resides during deployment of the stent in a blood vessel.
Claim 24
Dependent Claim
29 words
The method of claim 22, wherein: the biodegradable carrier material is selected to possess a molecular weight and molecular chain length to provide the layer with said sufficient elasticity.
Claim 25
Dependent Claim
163 words
A biomaterial device adapted to be placed in contact with human blood in connection with a medical, surgical, therapeutic, restorative, prosthetic, or pathological procedure; said device comprising: a biomaterial; and a thin, adhesive layer of material coating a surface of the biomaterial for continuous disintegration as a function of time when said layer is in contact with blood, said layer including: a biodegradable carrier material having biological compatibility with blood and tissue of the human body, and a substance incorporated in said carrier material and having at least one inhibitory property selected from the group consisting of anti-coagulant, anti-thrombotic, anti-inflammatory, anti-proliferative, anti-stenotic, and antibiotic, for timed release from said biodegradable carrier material with disintegration thereof when said device has been introduced into the body of the patient, said layer having a formulation, pattern and thickness selected according to the period of time over which said incorporated substance is to perform its inhibitory property action, said layer thickness being less than about 100 microns.
Claim 26
Dependent Claim
163 words
A biomaterial device adapted to be placed in contact with human blood in connection with a medical, surgical, therapeutic, restorative, prosthetic, or pathological procedure; said device comprising: a biomaterial; and a thin, adhesive layer of material coating a surface of the biomaterial for continuous disintegration as a function of time when said layer is in contact with blood, said layer including: a biodegradable carrier material having biological compatibility with blood and tissue of the human body, and a substance incorporated in said carrier material and having at least one inhibitory property selected from the group consisting of anti-coagulant, anti-thrombotic, anti-inflammatory, anti-proliferative, anti-stenotic, and antibiotic, for timed release from said biodegradable carrier material with disintegration thereof when said device has been introduced into the body of the patient, said layer having a formulation, pattern and thickness selected according to the period of time over which said incorporated substance is to perform its inhibitory property action, said layer thickness being less than about 100 microns.
Claim 27
Dependent Claim
59 words
The biomaterial device of claim 24, wherein: said biomaterial is a vascular stent of tubular configuration, and said layer is composed of material selected to render the layer sufficiently elastic to maintain its integrity despite change in the dimensions of the surface of the stent on which said layer resides during deployment of the stent in a blood vessel.
Claim 28
Dependent Claim
31 words
The biomaterial device of claim 25, wherein: the biodegradable carrier material is s elected to possess a molecular weight and molecular chain length to provide the layer with said sufficient elasticity.
Claim 29
Independent Claim
326 words
A method of providing a vascular stent of tubular configuration with the capability of localized action when deployed at a treatment site of an earlier procedure for opening the lumen of a blood vessel of a patient, wherein said action is to prevent both early thrombus formation on the stent and late restenosis attributable to the lumen opening procedure in the locality of the treatment site, without producing any other substantial systemic effects on the patient, said method comprising the steps of: preparing a liquid solution of biodegradable material having biological compatibility with blood and tissue of the human body, together with a substantially inert solvent; adding an anti-thrombotic substance to said liquid solution of the biodegradable material to produce a liquid coating material; adhesively applying the liquid coating material to an interior surface of the stent tubular configuration in a substantially continuous layer overlying said interior surface and having a formulation, pattern and thickness selected according to the period of time over which the coating material is to perform its anti-thrombotic action, and thereafter drying the coating material to a layer thickness less than about 100 microns for continuous disintegration thereof as a function of time when said stent layer is in contact with flowing blood; preparing a second liquid solution of said biodegradable material together with said substantially inert solvent; adding an anti-stenotic substance to said second liquid solution of biodegradable material to produce a second liquid coating material; adhesively applying the second liquid coating material to an exterior surface of the stent tubular configuration in a substantially continuous layer overlying said exterior surface and having a formulation, pattern and thickness selected according to the period of time over which the second coating material is to perform its anti-stenotic action, and thereafter drying the second coating material to a layer thickness less than about 100 microns for continuous disintegration thereof as a function of time when said layer is in contact with flowing blood.
Claim 30
Independent Claim
326 words
A method of providing a vascular stent of tubular configuration with the capability of localized action when deployed at a treatment site of an earlier procedure for opening the lumen of a blood vessel of a patient, wherein said action is to prevent both early thrombus formation on the stent and late restenosis attributable to the lumen opening procedure in the locality of the treatment site, without producing any other substantial systemic effects on the patient, said method comprising the steps of: preparing a liquid solution of biodegradable material having biological compatibility with blood and tissue of the human body, together with a substantially inert solvent; adding an anti-thrombotic substance to said liquid solution of the biodegradable material to produce a liquid coating material; adhesively applying the liquid coating material to an interior surface of the stent tubular configuration in a substantially continuous layer overlying said interior surface and having a formulation, pattern and thickness selected according to the period of time over which the coating material is to perform its anti-thrombotic action, and thereafter drying the coating material to a layer thickness less than about 100 microns for continuous disintegration thereof as a function of time when said stent layer is in contact with flowing blood; preparing a second liquid solution of said biodegradable material together with said substantially inert solvent; adding an anti-stenotic substance to said second liquid solution of biodegradable material to produce a second liquid coating material; adhesively applying the second liquid coating material to an exterior surface of the stent tubular configuration in a substantially continuous layer overlying said exterior surface and having a formulation, pattern and thickness selected according to the period of time over which the second coating material is to perform its anti-stenotic action, and thereafter drying the second coating material to a layer thickness less than about 100 microns for continuous disintegration thereof as a function of time when said layer is in contact with flowing blood.
Claim 31
Dependent Claim
57 words
The method of claim 27, wherein: at least one of the layers of first-mentioned and second coating material further includes at least one additive selected from the group consisting of anti-coagulant, anti-inflammatory, anti-proliferative, and antibiotic substances for timed release as the respective coating material disintegrates when the coated stent is placed in contact with the flowing blood.
Claim 32
Dependent Claim
39 words
The method of claim 27, wherein: said biodegradable material is a biodegradable synthetic polymer selected from the group consisting of polyglycolic acids, polylactids, polyhydroxybutyrates, polyhydroxy-valeriates, polydioxanons, modified starches, gelatins, modified celluloses, polyglycols, polyacrylic acids, polymethacrylic acids, and blends thereof.
Claim 33
Dependent Claim
29 words
The method of claim 27, wherein: said biodegradable material is a natural or synthetic aliphatic or hydroxy polymer of lactic acid, glycolic acid, or mixed polymers or blends thereof.
Claim 34
Dependent Claim
23 words
The method of claim 27, wherein: each of said layers of first-mentioned and second coating material has a thickness of about 10 microns.
Claim 35
Dependent Claim
58 words
The method of claim 27, wherein: each of said layers of first-mentioned and second coating material includes biodegradable carrier material selected to render the respective layer sufficiently elastic to maintain its integrity despite change in the dimensions of the surface of the stent on which said respective layer resides during deployment of the stent in a blood vessel.
Claim 36
Dependent Claim
30 words
The method of claim 32, wherein: the biodegradable carrier material is selected to possess a molecular weight and molecular chain length to provide the respective layer with said sufficient elasticity.
Claim 37
Dependent Claim
12 words
The method of claim 27, wherein said any anti-stenotic substance comprises tamoxifen.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-08-03 | 2002-02-02 | 2002-08-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-08-03 | 2006-02-02 | 2006-08-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-08-03 | 2010-02-02 | 2010-08-04 | $7700.00 | Window Closed / Lapsed |